These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 33318068)

  • 21. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.
    Aroda VR; Rosenstock J; Terauchi Y; Altuntas Y; Lalic NM; Morales Villegas EC; Jeppesen OK; Christiansen E; Hertz CL; Haluzík M;
    Diabetes Care; 2019 Sep; 42(9):1724-1732. PubMed ID: 31186300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo.
    Lavernia F; Blonde L
    Postgrad Med; 2020 Nov; 132(sup2):15-25. PubMed ID: 32815436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.
    Aroda VR; Aberle J; Bardtrum L; Christiansen E; Knop FK; Gabery S; Pedersen SD; Buse JB
    Lancet; 2023 Aug; 402(10403):693-704. PubMed ID: 37385279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis.
    Patel T; Nageeta F; Sohail R; Butt TS; Ganesan S; Madhurita F; Ahmed M; Zafar M; Zafar W; Zaman MU; Varrassi G; Khatri M; Kumar S
    Ann Med; 2023; 55(2):2239830. PubMed ID: 37498865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.
    Zinman B; Aroda VR; Buse JB; Cariou B; Harris SB; Hoff ST; Pedersen KB; Tarp-Johansen MJ; Araki E;
    Diabetes Care; 2019 Dec; 42(12):2262-2271. PubMed ID: 31530667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin.
    Wehler E; Lautsch D; Kowal S; Davies G; Briggs A; Li Q; Rajpathak S; Alsumali A
    Pharmacoeconomics; 2021 Mar; 39(3):317-330. PubMed ID: 33150566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
    Furusawa S; Nomoto H; Yokoyama H; Suzuki Y; Tsuzuki A; Takahashi K; Miya A; Kameda H; Cho KY; Takeuchi J; Nagai S; Taneda S; Kurihara Y; Nakamura A; Atsumi T;
    Diabetes Obes Metab; 2024 Mar; 26(3):961-970. PubMed ID: 38073422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme.
    Thethi TK; Pratley R; Meier JJ
    Diabetes Obes Metab; 2020 Aug; 22(8):1263-1277. PubMed ID: 32267058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
    Bain SC; Hansen BB; Malkin SJP; Nuhoho S; Valentine WJ; Chubb B; Hunt B; Capehorn M
    Diabetes Ther; 2020 Jan; 11(1):259-277. PubMed ID: 31833042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States.
    Cui J; Klepser DG; McAdam-Marx C
    J Manag Care Spec Pharm; 2021 Jul; 27(7):840-845. PubMed ID: 34185562
    [No Abstract]   [Full Text] [Related]  

  • 31. Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study).
    Nomoto H; Furusawa S; Nakamura A; Takeuchi J; Nagai S; Yokoyama H; Sakuma I; Taneda S; Kurihara Y; Aoki S; Miya A; Kameda H; Cho KY; Atsumi T; Miyoshi H
    BMJ Open; 2022 May; 12(5):e056885. PubMed ID: 35584872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
    Pratley RE; Aroda VR; Lingvay I; Lüdemann J; Andreassen C; Navarria A; Viljoen A;
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):275-286. PubMed ID: 29397376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials.
    Yabe D; Deenadayalan S; Horio H; Kaneto H; Jensen TB; Terauchi Y; Yamada Y; Inagaki N
    J Diabetes Investig; 2022 Jun; 13(6):975-985. PubMed ID: 35112504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real-world study (PIONEER REAL Canada).
    Jain AB; Reichert SM; Amadid H; Braae UC; Bradley RM; Kim JW; Soo V; Yale JF
    Diabetes Obes Metab; 2024 May; 26(5):1799-1807. PubMed ID: 38468125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GREATER COMBINED REDUCTIONS IN HbA
    Rodbard HW; Bellary S; Hramiak I; Seino Y; Silver R; Damgaard LH; Nayak G; Zacho J; Aroda VR
    Endocr Pract; 2019 Jun; 25(6):589-597. PubMed ID: 30865526
    [No Abstract]   [Full Text] [Related]  

  • 36. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
    Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A
    Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.
    Frías JP; Auerbach P; Bajaj HS; Fukushima Y; Lingvay I; Macura S; Søndergaard AL; Tankova TI; Tentolouris N; Buse JB
    Lancet Diabetes Endocrinol; 2021 Sep; 9(9):563-574. PubMed ID: 34293304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
    Martín V; Vidal J; Malkin SJP; Hallén N; Hunt B
    Adv Ther; 2020 Oct; 37(10):4427-4445. PubMed ID: 32862365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Li J; He K; Ge J; Li C; Jing Z
    Diabetes Res Clin Pract; 2021 Feb; 172():108656. PubMed ID: 33434602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme.
    Aroda VR; Bauer R; Christiansen E; Haluzík M; Kallenbach K; Montanya E; Rosenstock J; Meier JJ
    Diabetes Obes Metab; 2022 Jul; 24(7):1338-1350. PubMed ID: 35373893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.